Evidence map›Paper›PMID 40894151›Full record

ArticlemedRxiv : the preprint server for health sciences2025

High-throughput assay confirmation of a T-cell receptor pre-mRNA fragment as a blood-based inflammatory breast cancer biomarker.

Elizabeth A Ferrick-Kiddie, Sriya Dommaraju, Jun Yao, Christopher W Smith, Xiaoping Wang, Wendy A Woodward, MDACC Inflammatory Breast Cancer Team, Naoto T Ueno, Savitri Krishnamurthy, Alan M Lambowitz

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Elizabeth A Ferrick-KiddieDepartments of Molecular Biosciences and Oncology, University of Texas at Austin, Austin, TX 78712.ORCID 0000-0003-0088-5315
Sriya DommarajuDepartments of Molecular Biosciences and Oncology, University of Texas at Austin, Austin, TX 78712.ORCID 0009-0005-5709-3134
Jun YaoDepartments of Molecular Biosciences and Oncology, University of Texas at Austin, Austin, TX 78712.ORCID 0000-0002-1232-1587
Christopher W SmithDepartments of Molecular Biosciences and Oncology, University of Texas at Austin, Austin, TX 78712.ORCID 0000-0002-0828-3370
Xiaoping WangCancer Biology Program and Translational Clinical Research Program, University of Hawai'i Cancer Center, Honolulu, HI 96813.ORCID 0000-0003-4511-8638
Wendy A WoodwardMorgan Welch Inflammatory Breast Cancer Research Program and Clinic, University of Texas MD Anderson Cancer Center, Houston, TX 77030.ORCID 0000-0002-7935-739X
MDACC Inflammatory Breast Cancer Team
Naoto T UenoCancer Biology Program and Translational Clinical Research Program, University of Hawai'i Cancer Center, Honolulu, HI 96813.ORCID 0000-0002-0166-7275
Savitri KrishnamurthyMorgan Welch Inflammatory Breast Cancer Research Program and Clinic, University of Texas MD Anderson Cancer Center, Houston, TX 77030.ORCID 0000-0001-9030-4136
Alan M LambowitzDepartments of Molecular Biosciences and Oncology, University of Texas at Austin, Austin, TX 78712.ORCID 0000-0001-6036-2423

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
Group II Intron and Related Reverse TranscriptasesR35GM136216 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI ALAN M. LAMBOWITZ · 2020 to 2026
$6.0M
Deciphering the Mechanism of Lymphovascular Space Invasion Using a Lymphovascularized Bioengineering Breast Stromal PlatformR01CA284102 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI Bisrat G Debeb, Marissa Nichole Rylander · 2024 to 2026
$3.3M
Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancerR01CA258523 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI UENO, NAOTO T. · 2022 to 2025
$3.2M
Molecular Determinants of Inflammatory Breast CancerR01CA264529 · NCI · DUKE UNIVERSITY · PI DEVI, GAYATHRI · 2021 to 2025
$2.5M
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA258523NCI NIH HHS R01 CA264529NCI NIH HHS R01 CA284102NIGMS NIH HHS R35 GM136216
6 · The paper itself

Abstract

Previous TGIRT-seq analysis of RNAs in Inflammatory Breast Cancer (IBC) patient tumors, peripheral blood mononuclear cells (PBMCs) and plasma identified a short T-cell receptor mRNA fragment (

Indexed as

2’,3’-cyclic phosphatesDiagnosticsNonsense-Mediated RNA Decay pathwayRNA fragment in plasmaRNA splicing

Identifiers

PMID40894151
PMCPMC12393611

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.